Which has better earnings & valuation, GLSI or PLRX?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.54 N/A Pliant Therapeutics N/A N/A -$149.34M -$1.49 N/A

Is GLSI or PLRX more profitable?

Pliant Therapeutics' return on equity of -52.17% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -793.81% -295.32% Pliant Therapeutics N/A -52.17% -40.46%

Does the media favor ANIK or PLRX?

In the previous week, Anika Therapeutics had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Anika Therapeutics and 1 mentions for Pliant Therapeutics. Anika Therapeutics' average media sentiment score of 0.53 beat Pliant Therapeutics' score of -0.09 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PYXS or PLRX more profitable?

Pliant Therapeutics' return on equity of -52.17% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% Pliant Therapeutics N/A -52.17% -40.46%

Does the media prefer PYXS or PLRX?

In the previous week, Pyxis Oncology had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of -0.09 beat Pyxis Oncology's score of -0.40 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACIU or PLRX?

In the previous week, AC Immune had 6 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for AC Immune and 1 mentions for Pliant Therapeutics. AC Immune's average media sentiment score of 1.19 beat Pliant Therapeutics' score of -0.09 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IVVD or PLRX?

In the previous week, Invivyd and Invivyd both had 1 articles in the media. Invivyd's average media sentiment score of 1.34 beat Pliant Therapeutics' score of -0.09 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pliant Therapeutics (PLRX) Competitors

$1.12 -0.02 (-1.32%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.14 +0.02 (+1.69%)

As of 04:09 AM Eastern

Compare

PLRX vs. GLSI, ANIK, PYXS, ACIU, and IVVD

Should you buy Pliant Therapeutics stock or one of its competitors? Pliant Therapeutics's main competitors and comparable companies include Greenwich LifeSciences (GLSI), Anika Therapeutics (ANIK), Pyxis Oncology (PYXS), AC Immune (ACIU), and Invivyd (IVVD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pliant Therapeutics compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Pliant Therapeutics' return on equity of -52.17% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
Pliant Therapeutics	N/A	-52.17%	-40.46%

In the previous week, Pliant Therapeutics had 1 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 1 mentions for Pliant Therapeutics and 0 mentions for Greenwich LifeSciences. Pliant Therapeutics' average media sentiment score of -0.09 beat Greenwich LifeSciences' score of -1.32 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Greenwich LifeSciences	Negative
Pliant Therapeutics	Neutral

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.49	N/A

Greenwich LifeSciences has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Greenwich LifeSciences currently has a consensus price target of $69.00, suggesting a potential upside of 294.06%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 166.67%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Pliant Therapeutics beats Greenwich LifeSciences on 7 of the 12 factors compared between the two stocks.

How does Pliant Therapeutics compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anika Therapeutics has higher revenue and earnings than Pliant Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.42	-$10.88M	-$0.27	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.49	N/A

Pliant Therapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Pliant Therapeutics	N/A	-52.17%	-40.46%

In the previous week, Anika Therapeutics had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Anika Therapeutics and 1 mentions for Pliant Therapeutics. Anika Therapeutics' average media sentiment score of 0.53 beat Pliant Therapeutics' score of -0.09 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anika Therapeutics currently has a consensus price target of $22.00, suggesting a potential upside of 7.95%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 166.67%. Given Pliant Therapeutics' higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Anika Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Summary

Anika Therapeutics beats Pliant Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Pyxis Oncology had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of -0.09 beat Pyxis Oncology's score of -0.40 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pyxis Oncology has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pyxis Oncology presently has a consensus target price of $8.75, suggesting a potential upside of 171.74%. Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 166.67%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Pyxis Oncology has higher revenue and earnings than Pliant Therapeutics. Pyxis Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	19.38	-$79.62M	-$1.41	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.49	N/A

Pliant Therapeutics' return on equity of -52.17% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Summary

Pyxis Oncology beats Pliant Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to AC Immune?

AC Immune (NASDAQ:ACIU) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

AC Immune has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

AC Immune currently has a consensus price target of $7.50, suggesting a potential upside of 165.02%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 166.67%. Given Pliant Therapeutics' higher possible upside, analysts clearly believe Pliant Therapeutics is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

AC Immune has higher revenue and earnings than Pliant Therapeutics. AC Immune is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	66.82	-$85.03M	-$0.54	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.49	N/A

Pliant Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Pliant Therapeutics' return on equity of -52.17% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Pliant Therapeutics	N/A	-52.17%	-40.46%

In the previous week, AC Immune had 6 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for AC Immune and 1 mentions for Pliant Therapeutics. AC Immune's average media sentiment score of 1.19 beat Pliant Therapeutics' score of -0.09 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

51.4% of AC Immune shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

AC Immune beats Pliant Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to Invivyd?

Invivyd (NASDAQ:IVVD) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

70.4% of Invivyd shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 12.3% of Invivyd shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Invivyd has higher revenue and earnings than Pliant Therapeutics. Invivyd is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	5.09	-$52.49M	-$0.33	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.49	N/A

Invivyd has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Pliant Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Pliant Therapeutics' return on equity of -52.17% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Pliant Therapeutics	N/A	-52.17%	-40.46%

In the previous week, Invivyd and Invivyd both had 1 articles in the media. Invivyd's average media sentiment score of 1.34 beat Pliant Therapeutics' score of -0.09 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Invivyd presently has a consensus target price of $8.00, indicating a potential upside of 766.65%. Pliant Therapeutics has a consensus target price of $3.00, indicating a potential upside of 166.67%. Given Invivyd's stronger consensus rating and higher probable upside, equities research analysts clearly believe Invivyd is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Invivyd beats Pliant Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$70.59M	$3.98B	$7.31B	$13.28B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.76	13.88	274.10	25.70
Price / Sales	N/A	1,437.48	672.61	90.85
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.38	15.45	10.48	6.32
Net Income	-$149.34M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-0.44%	-1.68%	-0.68%	0.17%
1 Month Performance	-1.32%	-6.15%	-3.18%	-3.27%
1 Year Performance	-22.95%	30.67%	15.13%	5.58%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	1.4759 of 5 stars	$1.13 -1.3%	$3.00 +166.7%	-22.9%	$70.59M	N/A	N/A	49	Positive News Gap Down
GLSI Greenwich LifeSciences	2.0681 of 5 stars	$19.12 +2.9%	$69.00 +260.9%	+59.5%	$280.84M	N/A	N/A	13	Negative News
ANIK Anika Therapeutics	3.3818 of 5 stars	$20.94 +1.2%	$22.00 +5.1%	+123.5%	$280.38M	$112.82M	N/A	235	Analyst Forecast
PYXS Pyxis Oncology	3.0706 of 5 stars	$3.33 +4.3%	$8.75 +163.1%	+47.0%	$277.67M	$13.86M	N/A	56
ACIU AC Immune	3.2028 of 5 stars	$2.73 +2.8%	$7.50 +175.2%	+12.3%	$277.32M	$4.31M	N/A	106	Trending News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. GLSI, ANIK, PYXS, ACIU, and IVVD

How does Pliant Therapeutics compare to Greenwich LifeSciences?

Summary

How does Pliant Therapeutics compare to Anika Therapeutics?

Summary

How does Pliant Therapeutics compare to Pyxis Oncology?

Summary

How does Pliant Therapeutics compare to AC Immune?

Summary

How does Pliant Therapeutics compare to Invivyd?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. GLSI, ANIK, PYXS, ACIU, and IVVD

How does Pliant Therapeutics compare to Greenwich LifeSciences?

Is GLSI or PLRX more profitable?

Does the media prefer GLSI or PLRX?

Which has better earnings & valuation, GLSI or PLRX?

Which has more risk and volatility, GLSI or PLRX?

Do insiders and institutionals have more ownership in GLSI or PLRX?

Do analysts recommend GLSI or PLRX?

Summary

How does Pliant Therapeutics compare to Anika Therapeutics?

Do institutionals and insiders have more ownership in ANIK or PLRX?

Which has preferable earnings and valuation, ANIK or PLRX?

Is ANIK or PLRX more profitable?

Does the media favor ANIK or PLRX?

Do analysts recommend ANIK or PLRX?

Which has more volatility & risk, ANIK or PLRX?

Summary

How does Pliant Therapeutics compare to Pyxis Oncology?

Does the media prefer PYXS or PLRX?

Which has more risk & volatility, PYXS or PLRX?

Do insiders and institutionals hold more shares of PYXS or PLRX?

Do analysts prefer PYXS or PLRX?

Which has stronger earnings and valuation, PYXS or PLRX?

Is PYXS or PLRX more profitable?

Summary

How does Pliant Therapeutics compare to AC Immune?

Which has more risk and volatility, ACIU or PLRX?

Do analysts prefer ACIU or PLRX?

Which has better valuation and earnings, ACIU or PLRX?

Is ACIU or PLRX more profitable?

Does the media prefer ACIU or PLRX?

Do institutionals & insiders hold more shares of ACIU or PLRX?

Summary

How does Pliant Therapeutics compare to Invivyd?

Do institutionals & insiders believe in IVVD or PLRX?

Which has preferable earnings and valuation, IVVD or PLRX?

Which has more volatility and risk, IVVD or PLRX?

Is IVVD or PLRX more profitable?

Does the media prefer IVVD or PLRX?

Do analysts recommend IVVD or PLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools